1. Scrip
  2. >>Focus On Asia
  3. >>South Korea

SK Bio's 2020 Plans Undeterred By Pandemic

US Launch, IPO Moving Ahead

 
• By Jung Won Shin

The CEO of South Korea's SK Biopharmaceuticals talks about commercialization plans, strategy for epilepsy drug cenobamate and other pipeline assets and planned IPO.

Jeong Woo Cho
SK Bio CEO Jeong Woo Cho Outlines Plans • Source: SK Biopharmaceuticals

Although the COVID-19 situation is still serious in many countries, the pandemic has not significantly affected SK Biopharmaceuticals Co. Ltd.’s major business plans for this year, which include the US launch of Xcopri (cenobamate) and a sizable initial public offering in its domestic market, says the South Korean firm’s president and CEO Jeong Woo Cho.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

More from Focus On Asia

Novotech CEO On Flexible Trial Solutions Amid Tariff, Geopolitical Tensions

 
• By Anju Ghangurde

Novotech's CEO talks about rising interest for trials in regions with “regulatory agility” and “strategic insulation” from geopolitical complexity, especially among emerging and mid-sized biotech sponsors. Operational "reassessment” among some sponsors on exposure to China-based CROs/CRDMOs is another area he discussed.

Akeso Wins US Approval For PD-1 Antibody In NPC, Partly On US Data

 
• By Dexter Jie Yan

Akeso’s penpulimab will be the second to hit the US market for nasopharyngeal carcinoma, but the first to win FDA approval for the indication based on clinical findings in US patients.

CNS, Cardiometabolics A Bright Spot In Recent Chinese VC/PE Fundings

 
• By Dexter Jie Yan

Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.